Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurol… Read more
Hemogenyx Pharmaceuticals Plc (HOPHF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 6.924x
Based on the latest financial reports, Hemogenyx Pharmaceuticals Plc (HOPHF) has a cash flow conversion efficiency ratio of 6.924x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.19 Million) by net assets ($-750.11K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hemogenyx Pharmaceuticals Plc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Hemogenyx Pharmaceuticals Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Hemogenyx Pharmaceuticals Plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hemogenyx Pharmaceuticals Plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
High Sierra Technologies Inc
PINK:HSTI
|
0.043x |
|
Vastland Indonesia
JK:VAST
|
0.092x |
|
Humpuss Intermoda Transportasi
JK:HITS
|
0.053x |
|
PMHS
PINK:PMHS
|
-0.045x |
|
Creative Medical Technology Holdings Inc
NASDAQ:CELZ
|
-0.209x |
|
CHRISTIAN DIOR - Dusseldorf Stock Exchang
DU:DIO
|
N/A |
|
Bakhu Holdings Corp
PINK:BKUH
|
0.044x |
|
Photon Energy N.V.
WAR:PEN
|
0.119x |
Annual Cash Flow Conversion Efficiency for Hemogenyx Pharmaceuticals Plc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Hemogenyx Pharmaceuticals Plc from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $853.49K | $-4.14 Million | -4.851x | -120.94% |
| 2023-12-31 | $2.78 Million | $-6.11 Million | -2.195x | -144.66% |
| 2022-12-31 | $3.24 Million | $-2.91 Million | -0.897x | -178.97% |
| 2021-12-31 | $8.17 Million | $-2.63 Million | -0.322x | +84.34% |
| 2020-12-31 | $875.68K | $-1.80 Million | -2.054x | -159.74% |
| 2019-12-31 | $-349.04K | $-1.20 Million | 3.438x | +343.75% |
| 2018-12-31 | $959.17K | $-1.35 Million | -1.410x | -563.74% |
| 2017-12-31 | $2.13 Million | $-452.98K | -0.212x | +30.96% |
| 2016-12-31 | $903.71K | $-278.15K | -0.308x | -130.05% |
| 2015-12-31 | $77.82K | $79.71K | 1.024x | -- |